<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599323</url>
  </required_header>
  <id_info>
    <org_study_id>19439</org_study_id>
    <nct_id>NCT03599323</nct_id>
  </id_info>
  <brief_title>Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)</brief_title>
  <official_title>Prospective, Non-interventional, Post-marketing, Multi-center, Single-cohort, Safety (Questionnaire) Investigation of Empecid L Cream (Clotrimazole 1%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SATO PHARMACEUTICAL , Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers already did trials that showed Empecid L Cream worked for patients with Vaginal
      yeast infection who were in those trials. In this trial, they want to learn if consumers that
      use the cream under the guidance of a pharmacist have any medical problems during the trial
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse event (AE) and serious adverse event (SAE) in consumers using Empecid L Cream.</measure>
    <time_frame>Up to one month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Types of AE recorded in Questionnaire</measure>
    <time_frame>Up to one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns and way of use of Empecid L Cream recorded in Questionnaire</measure>
    <time_frame>Up to one month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Vaginal Candida</condition>
  <arm_group>
    <arm_group_label>Clotrimazole 1% (Empecid L Cream, BAYB5097)</arm_group_label>
    <description>Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole 1% (Empecid L Cream, BAYB5097)</intervention_name>
    <description>Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).</description>
    <arm_group_label>Clotrimazole 1% (Empecid L Cream, BAYB5097)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The primary population of interest is composed of subjects 15 years or older and under 60
        years who purchase Empecid L Cream.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Consumers who self-select and are then deemed appropriate users of the product by the
        pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only
        in patients previously diagnosed and treated by a doctor).

        Exclusion Criteria:

          -  Patient with first episode

          -  Patient with allergy to Empecid Cream (Clotrimazole)

          -  Patient under 15 years old/ beyond 60 years old

          -  Pregnant women or women who may possibly be pregnant

          -  Patient with diabetes

          -  Patient who repeats indicated symptom frequently, have recurrent episodes (once every
             month or two, or twice or more within 6 months).

          -  Patients who does not know whether it is a recurrence symptom

          -  Patients who have a fever, chills, lower abdominal pain, back or shoulder pain,
             colored or bloody vaginal discharge, fishy-smelling vaginal discharge, cessation of
             menses, irregular or abnormal bleeding from the vagina, or ulcer, edema or erosion in
             the vagina or vulva suggesting they may have a different disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

